Cancer

Dr. Nelson’s lab focuses on determining how different hormones and metabolite factors impact breast and ovarian cancer progression.

Current cancer treatments include drugs that target standard protein synthesis in cells, which can kill cancer cells, but also targets healthy cells. To address this issue, associate professor of biochemistry and Cancer Center at Illinois (CCIL) member, Hong Jin, is focusing on a non-canonical...

Erik Nelson, professor of molecular and integrative physiology, has won a $4.5 million Era of Hope Scholar Award from the United States Department of Defense Breast Cancer Research Program.This prestigious award supports individuals early in their careers who have demonstrated significant potential...

In breast cancer tumors, a molecule produced when the body breaks down cholesterol hijacks the myeloid immune cells that normally arm T cells to fight cancer, a new study in mice found. Instead, the hijacked myeloid cells disarm the T cells and even tell them to self-destruct.

Breast cancer patients are 60 percent more likely to die of cancer after surviving a heart attack, according to a new study published in Nature Medicine.

A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient’s own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they...

Benita S. Katzenellenbogen, Professor of Molecular and Integrative Physiology at the University of Illinois at Urbana-Champaign, has been appointed Senior Advisor to the Director of the Cancer Center at Illinois (CCIL), Rohit Bhargava.

The University of Illinois School of Molecular and Cellular Biology is pleased to announce the inaugural recipient of the Julie and David Mead Graduate Fellowship.

Erik Nelson, Assistant Professor of Molecular and Integrative Physiology, has been named the 2020-2021 Gunsalus Scholar by the College of Liberal Arts and Sciences for his work on cholesterol metabolism and cancer.

Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM 1, a transcription factor that regulates the activity of dozens of genes. The new compounds suppress tumor growth in human cells and in mouse models of several types of human breast cancer.